CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease-Reference-Cited by-同舟云学术

CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease

Published:2019-08-23 Issue:10 Volume:19 Page:971-978
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Albshesh Ahmad¹^ORCID,Ben-Horin Shomron¹

Affiliation:

1. Department of Gastroenterology, Sheba medical center, Sackler School of Medicine Tel-Aviv University, Israel

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1653848

Reference79 articles.

1. Tumor Necrosis Factor (TNF)

2. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells

3. Cytokines and autoimmunity

4. Switching from originator to biosimilar infliximab – real world data of a prospective 18 months follow-up of a single-centre IBD population

5. European Medicine Agency. Procedural advice for users of the centralised procedure for similar biological medicinal products applications. EMA/940451/2011. www.ema.europa.eu/docs/enGB/documentlibrary/Regulatory and procedural guideline/2012/04/WC500125166.pdf

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure;Gut and Liver;2024-06-05

2. Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development;Antibodies;2024-02-26

3. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study;Biomedicines;2022-08-30

4. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis;BioDrugs;2021-11

5. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease;Gastroenterology;2021-06